ライフサイエンスコーパス: CD4 cell count

1 ntiretroviral therapy (cART) irrespective of CD4 cell count.

2 yone infected with HIV irrespective of their CD4 cell count.

3 ended antiretroviral therapy irrespective of CD4 cell count.

4 Prevalences were adjusted for age and CD4 cell count.

5 ity were disseminated tuberculosis and a low CD4 cell count.

6 ection with detectable viremia regardless of CD4 cell count.

7 and to stimulate complete recovery of normal CD4 cell count.

8 as, by contrast, independent of the mother's CD4 cell count.

9 , the Bio-Rad Avidity assay, viral load, and CD4 cell count.

10 ths are linked with continued improvement in CD4 cell count.

11 ssay (ELISA) in a fully automated manner for CD4 cell count.

12 y identical to that of the MAA that included CD4 cell count.

13 d between participants in strata of baseline CD4 cell count.

14 tion on gender distribution, viral load, and CD4 cell count.

15 virological failure, and mean differences in CD4 cell count.

16 infections in HIV-positive people with high CD4 cell count.

17 ations, such as opportunistic infections and CD4 cell counts.

18 quality of available data increase at lower CD4 cell counts.

19 re 0.944 for log(10) HIV-1 RNA and 0.840 for CD4 cell counts.

20 ation antiretroviral therapy (cART), at high CD4 cell counts.

21 tiretroviral therapy (ART) with high pre-ART CD4 cell counts.

22 All three regimens improved patients' CD4 cell counts.

23 lines recommend initiating ART regardless of CD4+ cell count.

24 ART initiation at diagnosis, irrespective of CD4(+) cell count.

25 per muL, 1.61 to 2.39; p<0.0001), decreased CD4 cell count (0.53 per 5 square-root cells per muL, 0.

26 In univariable analysis, higher time-updated CD4 cell count (0.78, 0.71-0.85, p=0.0001) was associate

27 -31), detectable HIV RNA (19; 9-31), and low CD4 cell count (13%; 4-21).

28 d Hispanic patients had lower median initial CD4 cell count (132 cells/mm(3)) than documented Hispani

29 pes; 44% women; median age, 35 years; median CD4 cell count, 151 cells/microL; median VL, 5.0 log10 c

30 up was 321 cells per muL higher, and average CD4 cell count 194 cells per muL higher than the deferre

31 e diagnostic algorithm (58.5% female; median CD4 cell count, 278/muL; WHO HIV stage I, 66.8%), 98 (10

32 ere randomly assigned (1:1) to point-of-care CD4 cell counts (366 compounds with 417 participants) or

33 CHM regimens users had baseline CD4 cell counts (380.11 +/- 240.59 cell/muL), approximat

34 stent plasma viremia of <200 copies/mL (mean CD4(+)-cell count, 475.1+/-307.9 cells/muL).

35 ction: 39 (45%) of 87 women with HIV and low CD4 cell counts, 52 (59%) of 88 women with HIV and high

36 sis, 98.3% on antiretroviral therapy, median CD4+ cell count 527 cells/mm 3, 86.6% with HIV-1 RNA < 5

37 in meters squared) was 25.8, and the median CD4 cell count 620/uL.

38 risk is increased in association with a low CD4+ cell count (a clinical measurement of immune status

39 ociated with normalisation were high pre-ART CD4 cell counts, a high CD4/CD8 ratio at baseline, and n

40 ignificantly associated with a difference in CD4 cell count after 1 year of treatment.

41 The dramatic changes in viral load and CD4 cell count after therapy initiation highlight the ov

42 itted infections were also observed at lower CD4 cell counts after adjusting for age.

43 ed for demographic factors, baseline HIV RNA/CD4 cell counts, AIDS defining events and the type of In

44 ith detectable HIV RNA, and those with lower CD4 cell counts (all P < .05).

45 hose with detectable HIV RNA, and with lower CD4 cell counts (all P<0.05).

46 83, 95% CI 0.70-0.99; I(2)=51%, adjusted for CD4 cell count and ART duration), and there was some evi

47 In adjusted analyses, entry CD4 cell count and CD4/CD8 ratio were associated with GB

48 that differ in the threshold used to measure CD4 cell count and HIV RNA viral load every 3-6 months (

49 ted for age, sex, race, cohort, time-updated CD4 cell count and HIV RNA were estimated in calendar pe

50 study suggests that DAART, independently of CD4 cell count and risky behavior, has a potentially str

51 Factors associated with higher CD4 cell count and viral load (VL) suppression<400 c/mL

52 The joint distribution of CD4 cell count and viral load over time was depicted in

53 Still, the CD4 cell count and viral load represent the laboratory p

54 The analyses of CD4 cell counts and CD4/CD8 ratios may provide valuable

55 berculosis diagnosed had significantly lower CD4 cell counts and hemoglobin levels, more advanced WHO

56 s likely to be receiving cART, and had lower CD4 cell counts and higher viral loads.

57 ated cancer and determined by differences in CD4 cell counts and human immunodeficiency virus (HIV) R

58 Longitudinal CD4 cell counts and plasma viral load measurements befor

59 ng, infant feeding counselling, referral for CD4 cell counts and treatment, home-based services, anti

60 However, in settings where both CD4 cell counts and viral load testing are routinely ava

61 s of HIV disease severity represented by low CD4(+) cell count and high viral load, assessed by multi

62 A subset of PLWHA who had a CD4(+) cell count and VL measurement near the time of th

63 rveillance and registry databases, including CD4(+) cell counts and VL.

64 odel to analyze associations between pre-ART CD4+ cell counts and death, attrition, and death or attr

65 IV) patients has been associated with higher CD4+ cell counts and lower HIV-1 viral loads, with the u

66 is did not develop, matched by age, sex, and CD4 cell count, and 37 unmatched HIV-infected patients w

67 ning illness, a greater 12-month increase in CD4 cell count, and a smaller risk of virologic failure

68 amples were assessed for HIV RNA viral load, CD4 cell count, and antiretroviral drug-resistant mutati

69 ecent calendar period, a higher contemporary CD4 cell count, and first-line regimens based on nonnucl

70 tion persisted after adjustment for age, the CD4 cell count, and HIV viral load at diagnosis.

71 oglobin level, albumin level, HIV infection, CD4 cell count, and HIV-1 RNA level.

72 fidence interval: 1.7, 3.2), reduced current CD4 cell count, and increased numbers of oral sex and "r

73 nel, and stratified by HIV-1 RNA viral load, CD4 cell count, and intention to use zidovudine, with th

74 wed for 5 years for HIV-1 plasma viral load, CD4 cell count, and mortality.

75 etroviral therapy (ART) at a higher vs lower CD4 cell count, and the longer-term harms associated wit

76 f monitoring strategies, including clinical, CD4 cell count, and viral load monitoring, alone and tog

77 vent rates stratified by person-time in age, CD4 cell count, and VL and ARV categories.

78 and mortality among PHIVY stratified by age, CD4 cell count, and VL and ARV status.

79 rates and life expectancy stratified by sex, CD4 cell count, and WHO disease stage at enrolment in ca

80 unts, 52 (59%) of 88 women with HIV and high CD4 cell counts, and 60 (67%) of 90 women in the HIV-uni

81 nts without HIV, 89 and 88 with HIV and high CD4 cell counts, and 91 and 91 with HIV and low CD4 cell

82 dex, combination antiretroviral therapy use, CD4 cell counts, and HIV RNA.

83 n 40 copies per mL, changes from baseline in CD4 cell counts, and the frequency of adverse events, ad

84 smoking status) and was apparent across all CD4 cell count, antiretroviral therapy, and viral load s

85 Individuals with cirrhosis or low current CD4 cell count are at highest risk of developing HCC or

86 Human immunodeficiency virus infection and CD4 cell count are only 2 of many factors associated wit

87 fected individuals with relatively preserved CD4 cell counts are at higher risk for lower respiratory

88 Early ART initiation and maintenance of high CD4 cell counts are essential to further reducing KS inc

89 Logistic regression analysis included CD4(+) cell count as a covariate.

90 bacterial infections, and mortality at lower CD4 cell counts, as expected.

91 ses, loss of LTNP status was associated with CD4 cell count at 10 years after seroconversion (p < 0.0

92 years (IQR 30-43), 45.4% were female, median CD4 cell count at admission was 76 cells/mul (IQR 23-206

93 ve time with NVL, and WHO clinical stage and CD4 cell count at ART initiation, rates of excess all-ca

94 The median CD4 cell count at baseline was 18 cells per muL (IQR 9-3

95 Median CD4 cell count at baseline was 339 cells/microL (interqu

96 ells; P = .004), while survivors had similar CD4 cell count at baseline, regardless of HTLV status.

97 ratified by plasma HIV-1 RNA viral loads and CD4 cell count at baseline.

98 h pre-ART and ART stages included older age, CD4 cell count at initiation, and male sex.

99 Median CD4 cell count at lymphoma diagnosis among IRIS cases wa

100 hed January 2002-December 2013 that reported CD4 cell count at presentation or ART initiation among a

101 an-Meier estimator stratified by the initial CD4 cell count at the period of continuous suppression i

102 start of the Masa programme in 2002, average CD4 cell counts at enrolment increased (from 101 cells/m

103 ran Africa, contributing to persistently low CD4 cell counts at treatment initiation.

104 is study suggest that HIV patients with high CD4+ cell counts at the time of ART initiation may be at

105 sex-treatment arm interaction, pretreatment CD4 cell count, baseline VL, and subtype, was still inde

106 cell count or re-present with persistent low CD4 cell counts because of poor adherence, resistance to

107 significantly increased with lower maternal CD4 cell count, before and after adjustment for maternal

108 lity was associated with older age and lower CD4 cell count (both P < .05).

109 partly explained by ART-induced increases in CD4 cell count, but not by increases in neutrophil count

110 Geometric means were calculated for CD4 cell counts by month and calendar year.

111 Point-of-care CD4 cell counts can improve linkage to HIV care among pe

112 bing the number or proportion of patients in CD4 cell count categories.

113 munodeficiency virus (HIV)-1 RNA level (VL), CD4 cell counts (CD4), subtype, and treatment failure du

114 x, entry regimen, duration of ART, and nadir CD4 cell count; CD4 and CD8 cell counts were also associ

115 ime-updated lagged and cumulative exposures (CD4 cell count, CD8 cell count, CD4/CD8 ratio, HIV RNA,

116 factors on the causal pathway (most notably, CD4 cell count, clinical signs of advanced HIV, and poor

117 a or serum samples without a requirement for CD4 cell count data.

118 odeficiency virus (HIV)-positive adults, low CD4 cell counts despite fully suppressed HIV-1 RNA on an

119 higher in those with comorbidities and lower CD4 cell counts, despite HIV viral suppression.

120 e, composition, turnover, HIV incidence, and CD4 cell count development.

121 CD4 cell counts did not influence the oral or BAL microb

122 9-1.73) for threshold 350, and 24 month mean CD4 cell count differences were 0.4 (-25.5 to 26.3) cell

123 f-care (318 compounds with 353 participants) CD4 cell counts done at one of three referral laboratori

124 for condomless sex, square-root-transformed CD4 cell count, drug use, and patient demographics.

125 However, changes in CD4 cell count during ART, which were similar between co

126 Viral load monitoring without CD4 cell count every 6-12 months provides the greatest r

127 CD4 cell counts fell to <200 cells/microL in 5.7% of mon

128 CD4 cell counts fell to <200 cells/microL in 7.4% patien

129 y virus type 1 (HIV-1) plasma viral load and CD4 cell count for 5 years after antiretroviral therapy

130 antiretroviral therapy (ART) irrespective of CD4 cell count for all patients with tuberculosis who al

131 The median CD4 cell count for women with HIV was 397 (interquartile

132 mula: see text]=1.47, 95% CI 0.26, 2.67) and CD4 + cell count ([Formula: see text]= - 0.68, 95% CI -

133 ian CD4 cell count or reconstructed the mean CD4 cell count from the presented data describing the nu

134 After exclusion of CD4 cell counts from the model, higher HIV RNA load at 1

135 HIV RNA of less than 50 copies per mL and a CD4 cell count greater than 350 cells per muL.

136 positive patients with tuberculosis who have CD4 cell counts greater than 220 cells per muL.

137 ness of ART to asymptomatic individuals with CD4 cell counts greater than 500/mm3 and shows sustained

138 ow-resource settings found ART initiation at CD4 cell counts greater than 500/mm3 associated with low

139 to the vaccine (six [7%] in the HIV and low CD4 cell count group, 12 [13%] in the HIV and high CD4 c

140 ll count group, 12 [13%] in the HIV and high CD4 cell count group, and 21 [23%] in the HIV-uninfected

141 ence was high even among patients with nadir CD4 cell count >200 cells/microL (140 per 100 000 person

142 ) and/or recent HIV infection (patients with CD4 cell count >=500/mm3 at HIV diagnosis; (PRHI) betwee

143 diagnosis soon after HIV infection (ie, with CD4 cell count >=500/muL or with acute HIV infection) an

144 ccal polysaccharide vaccine (PPSV23) and had CD4 cell counts >/= 200 cells/mm(3) and HIV viral loads

145 ted adults with prior PPSV23 vaccination and CD4 cell counts >/= 200 cells/mm(3).

146 by estimating the probability of maintaining CD4 cell counts >/=200 cells/microL during continuous HI

147 Comparing patients with current CD4 cell counts >/=700 cells/microL with those whose cou

148 ted patients with suppressed viral loads and CD4 cell counts >300 cell/muL could be reduced to annual

149 d annually in HIV-monoinfected patients with CD4 cell counts >300 cells/microL and HIV/HCV-coinfected

150 However, for patients with a CD4(+) cell count >500/microL, clinicians would defer AR

151 llow-up among WLHIV with higher contemporary CD4+ cell counts (>=200 cells/uL vs <200 cells/uL [cOR =

152 ion status (no infection, infection and high CD4 cell count [>350 cells per muL], and infection and l

153 [>350 cells per muL], and infection and low CD4 cell count [>50 to </=350 cells per muL]) and receiv

154 had a suppressed viral load and their median CD4 cell count had increased.

155 Adjusting for CD4 cell counts had no effect on decay estimates.

156 ere bacterial infections in people with high CD4 cell counts have not been well described.

157 After adjustment for age, CD4(+) cell count, hepatitis B or C virus infection, and

158 The risk of HZ was associated with low CD4 cell counts, high HIV RNA levels, low CD4/CD8 ratios

159 resents a treatment option for patients with CD4 cell counts higher than 200 cells per muL.

160 associated with weight gain including lower CD4 cell count, higher HIV type 1 RNA, no injection drug

161 gnancies occur in different contexts of age, CD4 cell count, HIV control, viral co-infections, or chr

162 nical parameters, including body mass index, CD4 cell count, HIV load, and C-reactive protein levels

163 arms were well-balanced with respect to age, CD4 cell count, HIV RNA load, and antiretroviral treatme

164 orbidities, HIV status and related measures (CD4 cell counts, HIV viral load, and use of highly activ

165 Demographic and HIV variables (nadir/entry CD4(+) cell count, HIV RNA level, antiretroviral therapy

166 d for all coinfected patients, regardless of CD4 cell count.HIV/human T-cell lymphotrophic virus type

167 Higher baseline log10 CD4+ cell count (HR, 0.50; 95% CI, .40-.63) and increasi

168 CD4 cell counts improved over time (Ptrend <.001) so tha

169 teristics, plasma HIV RNA, nadir and current CD4 cell count in blood, current CD8 cell count in blood

170 vere bacterial infection in people with high CD4 cell counts in a preplanned analysis of the START tr

171 INTERPRETATION: Point-of-care CD4 cell counts in a resource-limited HBCT setting doubl

172 ssified as "HIV-related," with similarly low CD4 cell counts in both groups.

173 monitoring strategies based on time-varying CD4 cell counts in virologically suppressed HIV-positive

174 T scores were negatively associated with the CD4+ cell count in male children (beta: -0.13, 95% confi

175 d, missing and filled teeth (DMFT) score and CD4+ cell counts in 142 children living with HIV aged 8-

176 or both among HIV-infected adults with high CD4+ cell counts in Ivory Coast.

177 line regimen, and calendar year, low current CD4 cell counts increased the risk of developing KS thro

178 CD4+ cell counts increased at doses >=50 mg.

179 emtricitabine, and efavirenz) regardless of CD4 cell count (intervention) or according to national g

180 The micro-a-fluidic CD4 cell count is achieved by eliminating operational fl

181 Whereas soon after starting cART low CD4 cell count is the dominant risk factor, detectable H

182 h rates, survival time, baseline and current CD4 cell count, last HIV-1 RNA plasma viral load (pVL),

183 After adjustment for age, CD4 cell counts, last HIV viral load, antiretroviral the

184 0 weeks for post-48-week switch at the first CD4 cell count less than 100 cells/mm(3) or non-Candida

185 an increased risk of HFrEF, and time-updated CD4 cell count less than 200 cells/mm3 compared with at

186 Reaching a CD4 cell count less than 200/muL until May 2008; after t

187 ults (aged >/=18 years) living with HIV with CD4 cell count less than or equal to 350 cells per muL w

188 decreased transmission risk in persons with CD4 cell counts less than 500/mm3.

189 ohort study to assess the effects of pre-ART CD4+ cell count levels on death, attrition, and death or

190 mes for HIV-positive people were obtaining a CD4 cell count, linkage to an HIV clinic, ART initiation

191 antiretroviral therapy coverage, firstly at CD4 cell count lower than 350 cells per muL, and then at

192 lower than 350 cells per muL, and then at a CD4 cell count lower than 500 cells per muL, using lower

193 ies/mL; 5% and 18% vs 2% of person-time with CD4 cell count <200/microL; P < .001 for each comparison

194 nt, before and after adjustment for maternal CD4 cell count <350 and 350-499 CD4/mm(3) (adjusted haza

195 adults (aged >/=21 years) with advanced HIV (CD4 cell counts </=125 cells per muL) and pulmonary tube

196 ART initiation for HIV-positive persons with CD4 cell counts </=500 cells/microL, a higher threshold

197 immunodeficiency virus-infected adults with CD4 cell counts <100/muL seems promising as a strategy t

198 l loads (VLs) >100,000 copies/mL and 47% had CD4 cell counts <200/mm 3.

199 PT class B or C at SVR (10.71 [1.32-87.01]), CD4 cell counts <200/uL at SVR time-point (4.42 [1.49-13

200 PT class B or C at SVR (10.71 [1.32-87.01]), CD4 cell counts <200/uL at SVR time-point (4.42 [1.49-13

201 , in hospitalized HIV-infected patients with CD4 cell counts <350/microL and microbiologically proved

202 s had HIV-1 RNA >=100 000 copies/mL, 21% had CD4+ cell count <200 cells/uL, and 31% enrolled <=48 hou

203 s had HIV-1 RNA >=100,000 copies/mL, 21% had CD4+ cell count <200 cells/uL, and 31% enrolled <=48 hou

204 injury post-ART initiation in patients with CD4+ cell counts <200 cells/mm3 and >=200 cells/ mm3 was

205 rd deviation, 28-40), and 17.6% had baseline CD4+ cell counts <50 cells/mm3.

206 trata of age (7-12, 13-17, and 18-30 years), CD4 cell count (<200, 200-499, and >/=500/muL), and a co

207 hopenia (ICL) is defined by persistently low CD4+ cell counts (<300 cells/muL) in the absence of a ca

208 n a prospective cohort of patients with AHD (CD4 cell count, <=200/mul) receiving CD4 count testing,

209 A total of 5,083 (87.8%) having at least one CD4 cell count measure were included from 2005 to 2013.

210 For more than two decades, CD4 cell count measurements have been central to underst

211 ] vs 32 of 362 [8.8%]) and had lower current CD4 cell counts (median, 230 vs 383 cells/microL), lipid

212 ance rates (11% vs 30%; P = .003) and higher CD4(+) cell counts (median, 275 vs 213 cells/microL; P =

213 developing countries, simple and affordable CD4 cell counting methods are urgently needed in resourc

214 ted settings in the near term, point of care CD4 cell counts might have a role in prioritising care a

215 ected adults, irrespective of ART status and CD4 cell count, might be warranted.

216 From our data, it can be inferred that CD4 cell count monitoring can be safely performed annual

217 Regular CD4 cell count monitoring confers a benefit over clinica

218 We determined whether CD4 cell count monitoring could be reduced in monoinfect

219 It has been suggested that routine CD4 cell count monitoring in human immunodeficiency viru

220 ut evidence supporting similar reductions in CD4 cell count monitoring is lacking for this population

221 adjusting for sex, ethnicity, hypertension, CD4 cell count, nadir CD4 <200u/L, and time since HIV di

222 The main exposure variable was maternal CD4 cell count near delivery.

223 Of patients with a CD4 cell count of 220-349 cells per muL, 26 (7.9%) of 33

224 until May 2008; after this date, reaching a CD4 cell count of 250/muL or less, consistent with the s

225 Of monoinfected patients with an initial CD4 cell count of 300-349 cells/microL, 95.6% maintained

226 a median age of 39 years (33-45), and median CD4 cell count of 441 cells per mm(3) (294-628).

227 of 6.0% (95% CI 5.8-6.2) among people with a CD4 cell count of less than 100 cells per muL, with 278

228 tients who were HIV positive with a baseline CD4 cell count of less than 100 cells per uL were exclud

229 ith a VL of 400 copies/mL or more and with a CD4 cell count of less than 200/microL compared with 7-

230 d their clients to meet WHO eligibility of a CD4 cell count of less than 500 cells per muL could aver

231 rial in ART-naive HIV-positive patients with CD4 cell count of more than 500 cells per muL assigned t

232 Eligible participants had CD4 cell counts of >/=500 cells/microL and were not taki

233 ) 0%, p=0.94) and for each increase in nadir CD4 cell counts of 100 cells per muL, there was a 40% de

234 on cART (viral load <50 copies per mL) with CD4 cell counts of 400 x 10(6) cells per L or greater.

235 Individuals enrolling in care with CD4 cell counts of 500 cells per muL or more, and with W

236 greater than 1000 HIV RNA copies per mL and CD4 cell counts of fewer than 500 cells per muL, except

237 ients initiating antiretroviral therapy with CD4 cell counts of less than 50 cells per muL.

238 ment in ART group during the first 6 months, CD4 cell counts of patients in CHM group and CHM combine

239 CD4 cell counts of the combined group remained much lowe

240 f 8.3 years (IQR, 8.59 years) and had median CD4(+) cell counts of 256 (IQR, 284) with undetectable H

241 stment for latest HIV RNA level, but not for CD4 cell count or cancer risk factors, attenuated the ef

242 st or an investigator to correctly model the CD4 cell count or disease biomarkers of a patient in the

243 e with advanced HIV infection and with a low CD4 cell count or re-present with persistent low CD4 cel

244 We abstracted the mean or median CD4 cell count or reconstructed the mean CD4 cell count

245 treatment programme from 2005 to 2016 with a CD4 cell count or viral load recorded in South Africa's

246 ren and adolescents entering HIV care with a CD4 cell count or viral load test result by calendar per

247 nal CMV viruria was not associated with mean CD4 cell counts or HIV viral load but was associated wit

248 es should consider reducing the frequency of CD4 cell counts or not doing routine CD4 monitoring for

249 breastfeeding women who started ART with low CD4 cell counts or World Health Organization clinical st

250 ne and placebo participants were observed in CD4+ cell counts or plasma HIV-1 RNA over the first year

251 significantly influenced by HIV RNA levels, CD4+ cell counts, or antiretroviral therapy.

252 e intent ( P = .003), and those with a lower CD4 cell count ( P = .036).

253 Higher nadir CD4 cell count (P = .01) and plasma HIV RNA <50 copies/m

254 risk of lung cancer was associated with low CD4 cell count (p trend=0.001), low CD4/CD8 ratio (p tre

255 Patients with T0 KS had higher CD4 cell counts (P < .001); 90% of patients with T0 KS w

256 notype, antiretroviral regimen, HCV subtype, CD4 cell count, previous response to HCV treatment, HCV

257 rum lipid levels, HIV replication, low nadir CD4(+) cell count, protease inhibitor use, comorbid cond

258 started before or with ART, irrespective of CD4 cell count, reduces morbidity and mortality with ben

259 However, the median CD4 cell count remained below normal levels throughout f

260 HIV-RNA levels remained controlled and CD4 cell counts remained stable in all patients througho

261 cell counts, and 91 and 91 with HIV and low CD4 cell counts, respectively).

262 t was in those not infected, irrespective of CD4 cell count, resulting in lower levels of serotype-sp

263 disappeared after adjustment for the current CD4 cell count (RR, 1.03; 95% CI, .81-1.32).

264 Baseline weight, CD4 cell count status, and hemoglobin level were strongl

265 ity compared with uninfected patients at all CD4 cell count strata (>/=500/muL: IRR, 1.92; 95% CI, 1.

266 s per muL (Jan 1, 2016-Sept 30, 2016) to any CD4 cell count (test and treat, Oct 1, 2016-March 31, 20

267 ues advocate continued provision of baseline CD4 cell count testing in HIV care in low- and middle-in

268 delines now recommend limited use of routine CD4 cell count testing in human immunodeficiency virus (

269 sease staging with referral laboratory-based CD4 cell count testing is a key barrier to the initiatio

270 eferral, and then (1:1) either point-of-care CD4 cell count testing or referral for CD4 testing.

271 f front-line health workers, a point-of-care CD4 cell count testing platform, a revised counselling a

272 ng with counsellor support and point-of-care CD4 cell count testing would increase uptake of ART and

273 ormed using leftover blood drawn for routine CD4 cell count testing.

274 in multivariable analysis, particularly the CD4 cell count, the HR for immediate-initiation group mo

275 es, taking into consideration immune status, CD4 cell counts, the presence of systemic disease, and t

276 formula to compare 10-year mortality under 3 CD4 cell count thresholds for therapy initiation among 3

277 tform holds great promise for offering rapid CD4 cell count to scale up much needed ART in resource-c

278 After adjustment for age, BMI, sex, CD4 cell count, triglycerides, and separately adding sCD

279 After adjustment for age, BMI, sex, CD4 cell count, triglycerides, and separately adding sCD

280 h human immunodeficiency virus regardless of CD4 cell count under actual clinical conditions.

281 emia categories, accounting for time-varying CD4 cell count using marginal structural models.

282 ed information about the association of age, CD4 cell count, viral load (VL), and antiretroviral (ARV

283 ), and 81.6% were HIV infected; their median CD4 cell count was 47 cells/mul.

284 Median age was 40 years (IQR 35-48), CD4 cell count was 683 cells per muL (447-935), and body

285 CD4 cell count was inversely associated with mortality,

286 During follow-up, CD4 cell count was measured on average every 4.0 months

287 The median CD4(+)cell count was 612/muL, and the HIV load was <50 c

288 The median age was 51 years, and the median CD4+ cell count was 651/uL.

289 or factors that changed over time, including CD4 cell count, we detected no decreases in AIDS-related

290 Median baseline pVL and CD4 cell count were 9544 copies/mL (inter quartile range

291 Older age, cirrhosis, and low current CD4 cell count were associated with a higher incidence o

292 ned to immediate ART or deferral until their CD4 cell counts were lower than 350 cells per muL.

293 CD4 cell counts were measured every 12 weeks in both gro

294 ious ART experience had greater increases in CD4 cell counts, whereas black people and people who inj

295 iation, particularly among patients with low CD4 cell counts, whereas other cancers increased with ti

296 CD4 cell counts will continue to play an important part

297 The effect was modified by CD4 cell count with protection conferred if CD4 count wa

298 ed with higher IL-6 levels, and higher nadir CD4(+) cell counts with lower IL-6 levels.

299 lasma viral load [PVL], and nadir or current CD4 cell count) with outcomes of anal high-risk HPV prev

300 uals remain AIDS-free with a high and stable CD4 cell count without antiretroviral therapy (ART) for